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Technological advances in genetics have made feasible and affordable large studies to iden-
tify genetic variants that cause or modify a trait. Genetic studies have been carried out to
assess variants in candidate genes, as well as polymorphisms throughout the genome, for
their associations with heritable clinical outcomes of cystic fibrosis (CF), such as lung
disease, meconium ileus, and CF-related diabetes. The candidate gene approach has iden-
tified some predicted relationships, while genome-wide surveys have identified several
genes that would not have been obvious disease-modifying candidates, such as a methionine
sulfoxide transferase gene that influences intestinal obstruction, or a region on chromosome
11 proximate to genes encoding a transcription factor and an apoptosis controller that
associates with lung function. These unforeseen associations thus provide novel insight
into disease pathophysiology, as well as suggesting new therapeutic strategies for CF.
Cystic fibrosis (CF) is a Mendelian “mono-genic” recessive genetic disorder caused by
mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) gene (Welsh et al.
2001). There is a broad range of age-of-onset
and disease activity for different organ systems
in CF, including lung disease, meconium ileus,
diabetes, and liver disease, even for CF patients
who are homozygous for the most common
mutation, F508del (Cutting 2010). Therefore,
non-CFTR genetic variation and/or environ-
mental influences must contribute to the vari-
ability of clinical phenotypes.
To enhance understanding of the pathogen-
esis of organ-system disease in CF and identify
novel therapies, it is key to determine the mag-
nitude of environmental and genetic effects of
non-CFTR gene modifiers on clinical pheno-
types. If variability in disease largely reflects
environmental influences, there should be in-
tensified focus on these factors, which might
include the intensity of medical care, treatment
of different types of lung infections, socioeco-
nomic status, and effect of geographical tem-
perature (Schechter 2004; Collaco et al. 2010,
2011). If the variability in clinical phenotypes
largely reflects genetic variation in the genome,
it is key to determine which genes are involved,
and the mechanism of biological effects. Re-
cent evidence indicates that there is a strong
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influence of non-CFTR genetic variants on clin-
ical phenotype in CF, but most of the genetic
variation has not yet been defined (Mekus et al.
2000; Vanscoy et al. 2007).
Recent advances in genetic technology and
the formation of The International CF Gene
Modifier Consortium put CF at the cutting
edge of gene-modifier research in “monogenic”
disorders. This combination of events provides
a critical opportunity for CF, because identifica-
tion of the most important gene modifiers will
provide insight into the mechanisms of disease
pathogenesis, and offer the potential for novel
prognostic approaches and therapies. This arti-
cle provides an overview and update on the sta-
tus of gene modifier research in CF.
HETEROGENEITY OF CF CLINICAL
PHENOTYPES RELATED TO CFTR
MUTATIONS
Overview
CF is the most common autosomal recessive dis-
order among Caucasians, and the median age
of survival is only 39 years, despite improved
treatments. The cystic fibrosis transmembrane
regulator (CFTR) gene encodes a 1480-amino
acid protein that functions as a cAMP-mediated
Cl2 channel, which plays a key role in hydrating
airway secretions and regulating other cellular
functions, including Naþ transport in airwayep-
ithelia (Welsh et al. 2001; Cutting 2010). Because
clinical disease in CF results primarily from mu-
tations in CFTR, CF is termed a “monogenic”
disorder. There are .1500 mutations in CFTR
(see Cystic Fibrosis Gene Analysis Consortium,
www.genet.sickkids.on.ca/cftr/) and the most
prevalent mutation results in deletion of phenyl-
alanine at position 508 (F508del), which occurs
on 70% of CF chromosomes in the U.S.
Heterogeneity of Disease Related to
Mutations in CFTR
There is strong correlation between the gener-
al type of CFTR mutation and disease pheno-
type. Specifically, those mutations without re-
sidual function, such as F508del, are associated
with pancreatic exocrine insufficiency, whereas
10% of CFTR mutations retain some residual
function and are associated with pancreatic exo-
crine sufficiency. Indeed, patients with at least
one copy of a mutant CFTR allele with residu-
al function have better nutritional status and
milder lung disease, even though there is broad
heterogeneity of disease severity (Mickle and
Cutting 1993, 2000; The Cystic Fibrosis Geno-
type-Phenotype Consortium 1993). The devel-
opment of meconium ileus, CF related diabetes
(CFRD), and severe CF liver disease with portal
hypertension (CFLD) is largely confined to pa-
tients with CFTR mutations with no residual
function (Blackman et al. 2006, 2009b; Sontag
et al. 2006; Bartlett et al. 2009; Moran et al.
2009). However, among patients carrying two
mutations with no residual function, there is
also a very broad range of lung disease severity,
and there are strikingly different prevalences of
meconium ileus, diabetes, and liver disease.
HERITABILITY OF CLINICAL PHENOTYPES
Overview
Before extensive genetic data was available, the
prevailing concept was that the heterogeneity
of clinical phenotypes reflected differing mag-
nitudes of genetic versus environmental influ-
ences (Fig. 1) (Castaldo et al. 2001; Drumm
2001; Davies et al. 2005). For example, obstruc-
tive azoospermia (congenital bilateral absence
of the vas deferens, CBAVD), occurs in nearly
all CF males, regardless of whether the CFTR
mutation has some residual function, or not;
therefore, CBAVD is determined by genetics un-
derlying mutations in CFTR (Cutting 2010).
CF-related diabetes (CFRD) and severe CF liver
disease with portal hypertension (CFLD) is lim-
ited to patients with two CFTR mutations with-
out residual function (Bartlett et al. 2009; Black-
man et al. 2009b; Moran et al. 2009). CFLD
occurs before adulthood in the vast majority
of CF patients who develop CFLD. The preva-
lence of CFRD is age-dependent, and occurs in
25%–35% of CF adults. Lung disease occurs
in patients regardless of whether CFTR muta-
tions have residual function, or not, but the
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range of disease severity is very great; thus, there
are likely major contributions from both non-
CFTR genetic modifiers and environmental in-
fluences (Mekus et al. 2000; Vanscoy et al. 2007).
Formal studies of genetic heritability of
different clinical phenotypes have largely con-
firmed previous speculations (see above), and
clearly show major roles for non-CFTR genet-
ic variation in the different clinical phenotypes
(Table 1). Genes that cause many “monogenic”
disorders have been described, but there is little
knowledge of the other specific factors that con-
tribute to variability of the clinical phenotype.
Investigations of inbred mice provide evidence
that overall genetic background has a major
effect on clinical phenotype in monogenic























































Figure 1. Schematic display of the magnitude of the effect of mutant CFTR versus environmental influences and
modifier genes. (Image courtesy of Peter Durie, Toronto.)
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disorders, which is a concept that relates to non-
CFTR genetic influences on disease phenotype
in CF (Nadeau 2001). There are also CFTR-re-
lated “mono-organ” disorders, such as male in-
fertility, pancreatitis and sinusitis, which impli-
cate complex genetic variation as important in
mono-organ disease. Therefore, the study of
modifier genes in CF is well-grounded from a
conceptual perspective.
Lung
There is a broad range of lung disease severity,
even for patients who are F508del homozygotes.
This is illustrated in a representative population
of Canadian CF patients by great variability in
forced expired volume in 1 sec (FEV1) (Fig. 2),
which is a measure of airflow obstruction that
correlates with lung disease severity and survival
in CF. Two twin/sibling studies have concluded
that there is a strong non-CFTR genetic con-
tribution (0.54–1.0) to the CF lung pheno-
type (Table 1—“Heritability”). A key feature
for studying non-CFTR genotype-phenotype
relationships is the ability to define a meaning-
ful clinical phenotype in quantitative, or clear-
cut binary, terms. Successful studies involve
substantial effort to define the pertinent pheno-
type (see section below, “Challenges: Pheno-
types”).
Meconium Ileus
About 15%–20% of CF neonates are afflicted
by an intestinal blockage that develops in utero,
a concretion composed of meconium and mu-
cus, and characteristically forms in the distal
ileum. Evidence of this condition, known as
meconium ileus (MI), is often detected before
birth by ultrasound as a dense region on the
sonogram. Histologically, there is an increase
in the number and size of goblet cells, and elon-
gated villi and distended crypts are seen as well.
MI appears to be under nearly complete control
of genetic factors, as heritability of this trait
approaches 100% (Table 1).
CF-Related Diabetes
CF-related diabetes (CFRD) is a common co-
morbidity in CF, with about a fifth of adoles-
cents affected and nearly half of adults (Moran
et al. 2009). As a clinical entity, CFRD is distinct,
although sharing properties of type 1 and type 2
diabetes (T1DM and T2DM, respectively). Type
1 features include reduced b-cell mass and
diminished insulin secretion, but the etiology
is not one of autoimmunity. Similar to type 2
diabetes, the pancreases of CFRD patients dis-
play amyloid deposition (Couce et al. 1996).



























Figure 2. Lung disease severity assessed by FEV1 versus age in 1357 Canadian CF patients with biallelic loss-of-
function (pancreatic insufficient) mutations. (Image courtesy of Peter Durie, Toronto.)
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is rare, consistent with insulin secretion being
reduced but not absent. Unlike type 2 diabetes,
obesity is not a risk factor, nor are the dyslipi-
demia profiles characteristic of type 2 diabetes.
Whereas the morphometric and biochemi-
cal risk factors for T2DM do not appear to be
risk factors for CFRD, the genetics point to a
relationship between T2DM and CFRD. For ex-
ample, having a relative with T2DM increases
the risk of a CF patient for developing CFRD
(Blackman et al. 2009a). In fact, the heritabili-
ty of CFRD is high, approaching 1 (Table 1),
substantially higher than for T2DM, suggesting
that CFRD is much less influenced by environ-
mental factors, such as diet, than T2DM with
which it appears to share genetic etiology.
CF Liver Disease
CF liver disease begins with loss of CFTR (Cl2
channel) function on the apical membrane of
cholangiocytes. This dysfunction leads to de-
fective (sluggish) bile flow and an inflammato-
ry response with activation and proliferation
of hepatic stellate cells, which results in cholan-
gitis and fibrosis in focal portal tracts (Rowland
and Bourke 2011). However, only a small sub-
set (5%) of patients with CF develops severe
liver disease with portal hypertension (CFLD).
Moreover, CFLD occurs at a median age of only
10 years, and .90% of CFLD occurs by age 20
years; thus, non-CFTR genetic variations likely
contribute to risk for CFLD (Bartlett et al. 2009),
but there are no formal estimates of heritability.
Finally, there is also an increased prevalence of
CFLD in males (2:1) over females, suggesting a
role for gender and/or male/female hormones
in this disorder.
MODIFIER GENETICS AND RECESSIVE
MENDELIAN DISORDERS
Approaches to Study Genetic Modifiers in CF
The concept of gene modifiers in a Mendelian
disorder such as cystic fibrosis shares some fea-
tures, but is fundamentally different from the
concept of genetic variants in non-Mendelian,
complex genetic disorders, such as asthma. In
complex genetic disorders, genetic variants in-
teract with each other and the environment to
cause the disorder (Van Heyningen and Yeyati
2004). In contrast, cystic fibrosis results from
mutations in CFTR, and genetic variants that
affect pathogenesis of mutant CFTR modify
the severity of the phenotype (Drumm 2001;
Cutting 2010). Genetic variation that has little
effect in normal subjects may modify disease in
cystic fibrosis.
Two different types of genetic studies have
been used to discover gene modifiers in cystic
fibrosis, i.e., case-control association studies and
family-based (linkage) studies (Cutting 2010).
The case-control (association) study is usually
more robust for detecting common genetic
variants, in part because of the larger number
of subjects that can be enrolled in association
studies, as compared with family-based studies.
Enrollment into family-based twin/sibling link-
age studies is more challenging, but it allows
better definition of environmental versus genet-
ic effects on the phenotype. Thus, complemen-
tary studies employing both the association and
family-based methodologies would be optimal,
and this strategy has been undertaken in cystic
fibrosis by the International CF Gene Modifier
Consortium.
Challenges: Phenotypes
Studies of genetic effects on phenotype require
a meaningful and accurate definition of pheno-
type. For lung disease, FEV1 relates to clinical
disease severity and outcome; therefore, the de-
velopment of a quantitative lung phenotype has
been developed for CF, using multiple mea-
sures of FEV1 and adjusting for mortality attri-
tion (Taylor et al. 2011). This rigorous, quanti-
tative lung phenotype has been used in a GWAS
study of 3500 CF patients (Wright et al.
2011). For meconium ileus, a binary (yes/no)
approach is used to define phenotype, but re-
quires careful review of source documents to be
accurate (Wood et al. 2007; Sun et al. 2012). A
recent publication has also determined that the
heritability of chronic respiratory infection with
Pseudomonas aeruginosa is very strong (0.76–
0.85), which provides another lung phenotype
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that can be studied for genetic modifiers (Green
et al. 2012). For CF-related diabetes there is an
increasing prevalence with age; therefore, genet-
ic studies use age-of-onset (“survival”) type an-
alyses (Blackman et al. 2009b). For liver disease,
a binary (yes/no) approach is used, but this
requires extensive review of source documents
to accurately determine which patients have
severe liver disease with portal hypertension
(CFLD) (Bartlett et al. 2009). Many genetic
studies have been flawed by nonmeaningful or
imprecise definition of phenotype, but the CF
community has focused on establishing mean-
ingful and accurate phenotypes.
IDENTIFIED MODIFIERS OF DISEASE
PHENOTYPES BY CANDIDATE GENE
APPROACH
Concept
Initial searches for non-CFTR genetic variants
that influence pulmonary phenotype used the
candidate gene approach, which is based on bi-
ological plausibility. This approach is attractive
because testing a small number of carefully se-
lected candidates avoids severe penalties from
multiple comparisons during statistical analysis.
However, the candidate gene approach has sub-
stantial bias, because of incomplete understand-
ing of the pathophysiology of CF lung disease.
Because an association between a genetic vari-
ant and disease phenotype can reflect relatively
small differences in allele frequency, it is critical
to replicate any association in a separate pop-
ulation, preferably several times. In CF, many
candidate genes have been tested, but only a
few candidates have been tested in .1000 CF
patients, and only a few have been replicated
(Table 2). A comprehensive review of all gene
modifier studies in CF is beyond the scope of
this article, so we report a summary of candi-
date genes that have been replicated in at least
one organ in 2 populations entailing at least
500 individuals total (Table 2; see text below).
Several recent publications review all candidate
genes that have been tested in CF (Cutting 2005;
Davies et al. 2005; Knowles 2006; Collaco and
Cutting 2008).
Lung Disease
Lung disease in CF is linked to defective ion
transport, which leads to inadequate hydration
of airway mucus and results in defective muco-
ciliary and cough clearance. Acute and chron-
ic airway infection occurs secondary to defec-
tive mucociliary clearance, which contributes to
an inflammatory response and adversely affects
the phenotype. These defects of ion transport,
mucus clearance, and infection and inflamma-
tion leads to the development of bronchiectasis.
Therefore, genetic variation in many genes in
these pathways could modify the clinical phe-
notype, and be associated with more severe (or
milder) lung disease, and affect survival.
Multiple studies have tested whether func-
tional variants in mannose binding lectin
(MBL2) associate with lung disease severity in
CF. MBL2 is biologically plausible, because of
its role in innate immunity and the predilection
of MBL2 deficient patients to bacterial and viral
infection. Six studies involving .2000 CF pa-
tients have shown that MBL-deficient genotypes
(OO or AO) are associated with worse lung func-
tion (Table 2) (Gabolde et al. 1999; Garred et al.
1999; Davies et al. 2004; Yarden et al. 2004; Tre-
visiol et al. 2005; Dorfman et al. 2008), and three
studies reported earlier age of infection with
Pseudomonas aeruginosa (Ps. a.) (Table 2) (Tre-
visiol et al. 2005; Dorfman et al. 2008; McDougal
et al. 2010). Because severity of lung disease, Ps.
a. infection, and age are correlated, a modeling
framework addressed these confounding vari-
ables, and concluded that deficiency in MBL
predisposes to earlier infection with Ps. a. and
thereby leads to worse lung disease (McDougal
et al. 2010). Several studies did not report an
association of MBL deficient genotypes with
CF lung disease, which might reflect large num-
bers of older patients and/or other factors relat-
ed to bacterial infection (Cutting 2010).
Genetic variation in the endothelial recep-
tor type A (EDNRA) has been associated with
CF lung disease severity (Table 2), and repli-
cated in three additional populations of CF
patients (1478 total) (Darrah et al. 2010). The
variant EDNRA (rs5335) is in the 30 UTR, and
the risk allele for worse lung disease is associated
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with increased expression of EDNRA in cul-
tured human tracheal smooth muscle cells, as
well as increased proliferation of smooth muscle
cells that are homozygous for the risk variant.
Thus, the mechanism for adversely modifying
CF lung disease likely reflects increased smooth
muscle activity in airways and/or vasculature.
Transforming growth factor b1 (TGF-b1)
modifies risk for airways disease in asthma and
COPD, and has a key role in regulating airway
inflammation and remodeling; hence, TGF-b1
has been repeatedly studied as a modifier of
CF lung disease (Table 2). Alleles in the promo-
tor (-509) and first exon (codon 10) of TGF-b1
are associated with worse lung function, and
was replicated in the Genetic Modifier Study
(GMS) of .1300 CF patients (Drumm et al.
2005). This discovery was independently repli-
cated when haplotypes of alleles at -509 and
codon 10 were analyzed in a separate popula-
tion (Bremer et al. 2008). Further, other gene
and environmental interactions are relevant to












MBL2 REPLICATEDa REPLICATED Gabolde et al. 1999;
Garred et al. 1999;
Davies et al. 2004;
Yarden et al. 2004;




EDNRA REPLICATED Darrah et al. 2010
TGF-b1 REPLICATED Negativec Probably
negatived
Arkwright et al. 2000,
2003; Drumm et al.
2005; Brazova et al.,
2006; Bremer et al.
2008; Corvol et al.
2008; Dorfman
et al. 2008; Bartlett
et al. 2009; Faria
et al. 2009
IFRD1 Replicatedb Gu et al. 2009
IL8 Replicated Hillian et al. 2008
MSRA REPLICATED Henderson et al. 2012
ADIPOR2 Replicated Dorfman et al. 2009
TCF7L2 REPLICATED Blackman et al. 2009a
SERPINA1 Negative Probably
negative
Replicated Arkwright et al. 2000,
2003; Drumm et al.
2005; Brazova et al.
2006; Bremer et al.
2008; Corvol et al.
2008 Dorfman et al.
2008; Bartlett et al.
2009; Faria et al.
2009
aREPLICATED: seen in 3 populations with total 1000 individuals.
bReplicated: seen in 2 populations with total 500 individuals.
cNegative: negative in 3 populations with total 1000 individuals.
dProbably negative: negative in 2 populations with total 500 individuals.
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TGF-b1, because interactions with variants in
MBL2 and second-hand smoke exposure mod-
ify TGF-b1 association with lung disease. A few
small studies did not report the same association
of TGF-b1 and CF lung disease (Cutting 2010).
Genetic variation in the interferon-related
developmental regulator 1 (IFRD1) gene was
identified as one of six candidate regions, based
on study of 320 CF patients in the GMS study
with “mild” (n ¼ 160) versus “severe” (n ¼
160) lung disease (Table 2). Polymorphisms in
IFRD1 replicated in the larger GMS sample, and
then showed association in a family-based (twin
and siblings) population (Gu et al. 2009). In
vitro and studies in mice indicated that IFRD1
acts to modify neutrophil function during
bacterial infection, via transcriptional mecha-
nisms, but this gene has not been further repli-
cated in additional CF populations.
IL-8 is a cytokine that is well-recognized to
be associated with airways inflammation in CF,
and known to mediate neutrophil chemotaxis.
The association of IL-8 variants and CF lung
disease was first noted in 737 CF patients and
was most strongly shown in males (Table 2). The
replication was verified for males in an addi-
tional 385 patients. The mechanism appears to
reflect differential gene expression through IL-8
promoter variants.
Meconium Ileus
The heritability of MI (Table 1) clearly indicates
that genes other than CFTR are involved in its
etiology, but the candidate gene approach has
not been applied to this CF trait. A novel can-
didate region approach was used however, in
which a segment of mouse chromosome 7 that
was found to influence intestinal obstruction in
CF mice (Rozmahel et al. 1996) was examined
for the corresponding region of the human ge-
nome for its effect on MI. Initial reports indi-
cated that variants in this region did, in fact,
associate with MI (Zielenski et al. 1999), but a
causative gene was never identified and sub-
sequent studies failed to replicate this finding
(Blackman et al. 2006). Although the genetic
contribution to MI seems clear, the genes re-
sponsible remained elusive.
CF-Related Diabetes
The observation that family history of T2DM
increases risk for CFRD, as described above,
made obvious the need to test specific genes
associated with T2DM for similar associations
with CFRD. Thus, a candidate gene approach
was initiated and showed that single nucleotide
polymorphisms near the transcription factor
7-like 2 (TCF7L2) gene showed an association
with type 2 diabetes with an estimated odds
ratio of 1.5 per allele (Blackman et al. 2009b).
In addition to showing a specific genetic
relationship between T2DM and CFRD, this
study showed an important concept regard-
ing the confounding effects that nongenetic,
or environmental factors may have on genetic
studies, sometimes obscuring them. In this case,
the nongenetic influences appear to be pharma-
cology, specifically steroidal anti-inflammatory
drugs. Glucocorticoids are commonly used as
an anti-inflammatory treatment for CF, and it is
well established that a side effect of glucocorti-
coids is hyperglycemia, albeit transiently. Thus,
this important pharmacotherapy for the lungs
has the potential to mask differences in glyce-
mic levels that would be caused by genetic var-
iation. When controlling for the effect of this
steroidal treatment by examining patients not
recently using glucocorticoids, the risk associ-
ated with TCF7L2 alleles increased to 2.9 per
allele (Blackman et al. 2009b).
Other evidence of similarities to T2DM is
emerging as well. A screen of six genes associat-
ed with T2DM found that a polymorphism in
Calpain-10 associated nominally with response
to a glucose tolerance test (Derbel et al. 2006).
Other T2DM genes are sure to be tested in the
future, but as the effect of many of them is quite
small it remains to be seen whether the cohort
sizes available for CF studies will have the power
to detect them.
CF Liver Disease
CF liver disease with portal hypertension
(CFLD) occurs early in life in CF patients with
biallelic loss-of-function (pancreatic insuffi-
cient) mutations in CFTR. The largest two-stage
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study of CFLD focused on five candidate genes
that had previously been studied in CF “liver
disease,” but not all patients in previous studies
had portal hypertension (Bartlett et al. 2009).
The two-stage study showed strong association
(and replication) of the Z-allele of the a1-anti-
protease (SERPINA1) gene with CFLD in a total
of 260 patients with CFLD versus 1931 CF pa-
tients without CFLD (Table 2). The mechanism
is unclear, but probably does not reflect cumu-
lative efforts of the folding mutations in CFTR
(F508del) and SERPINA1 (Z-allele), because
these two genes are predominately expressed in
two different cell types (cholangiocytes and he-
patocytes, respectively) in the liver. Variants in
TGF-b1 were associated with CFLD in stage 1,
but did not replicate in stage 2 of the CFLD study
(Bartlett et al. 2009).
IDENTIFIED MODIFIERS OF DISEASE
PHENOTYPE BY GWAS ASSOCIATION
AND LINKAGE
The ability to perform unbiased study of rela-
tively common genetic polymorphisms across
the entire human genome in a cost-effective
fashion has recently come-of-age. To maximize
power to detect novel modifiers of CF pheno-
types using genome-wide approaches, three dif-
ferent study groups have joined forces and
created a consortium with .3500 well-pheno-
typed CF patients to study modifiers in CF. This
consortium includes three different study de-
signs: (1) Gene Modifier Study (GMS), which
enrolled F508del homozygotes with extremes-
of-lung phenotype (Drumm et al. 2005); (2) Ca-
nadian Genetic Study (CGS), which enrolled
population-based CF patients; and (3) family-
based, twins and siblings (TSS), which enrolled
patients from families with more than one CF
child. The GMS and CGS are best-suited for as-
sociation analysis of unrelated patients, whereas
the TSS (family-based) study can be used for
both linkage and association analyses. Using
this complementary study design allows for dis-
covery by association (or by linkage) and then
testing for replication in the alternate popula-
tion(s).
Lung Disease
The combined genome-wide association and
linkage study (GWALS) genotyped 3467 CF pa-
tients (Illumina 610 Quad platform) to identi-
fy genomic regions associated with CF lung
disease severity. The strongest association sig-
nal (p ¼ 3  1028) was located at chromo-
some11p13, intergenic to EHF and APIP and
replicated in the TSS (family-based) patients
(Fig. 3) (Wright et al. 2011). EHF is an epithe-
lia-specific Ets transcription factor, and may be
an important regulator of differentiation under
stress conditions and inflammation. APIP is a
known inhibitor of apoptosis, and eQTLs for
APIP in lymphocytes suggests the risk SNP in
this region may be associated with increased ex-
pression of APIP, implying that inhibition of
apoptosis worsens CF lung disease. This is con-
gruent with the notion that inhibition of apo-
ptosis in airways delays clearance of neutrophils
and leads to a hyper-inflammatory state (Dib-
bert et al. 1999; Harris et al. 2005). Inhibition of
apoptosis may also contribute to goblet cell
metaplasia, which is a feature of CF airways dis-
ease (Dibbert et al. 1999; Harris et al. 2005).
Polymorphisms in the intergenic region of
chr11p13 may also affect regulatory domains,
which could alter expression of EHF and APIP
and other genes in the region, including ELF5,
PDHX, and CD44. Studies are ongoing to elu-
cidate the mechanism of disease pathogenesis
from genomic polymorphisms at chromo-
some11p13.
There was also a near-significant genome-
wide association at the chromosome 6p21.3
HLA class II DR locus. Genetic variation at
this locus has been widely recognized to play a
role in multiple infections and inflammatory
disorders, which would be relevant to the in-
fections and inflammatory nature of CF airway
disease (Handunnetthi et al. 2010). This locus is
very genetically heterogeneous, and studies are
underway to define the specific DR allele that
is associated with severity of CF lung disease.
There were five other regions of suggestive
association (Wright et al. 2011), which will be
further analyzed by an ongoing GWAS in an
additional 3500 CF patients. Two previously
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reported modifiers of CF lung disease, TGF-b1
and IFRD1, did not achieve genome-wide sig-
nificance. However, TGF-b1 achieved p-values
of 1023 to 1024 in GMS patients, depending on
the covariates used in the analyses.
Linkage analysis of 486 sibling pairs from
the family-based study identified a robust link-
age signal at chr20q13.2 (LOD ¼ 5.03). A re-
gion below the linkage peak was analyzed for
association in the GMS and CGS patients, and
replicated under a region-wide analytical ap-
proach (p ¼ 1  1024). The chr20p13.2 link-
age region contains five genes (CBLN4; MC3R;
CASS4; CSTF1; AURKA) that are expressed
in fetal or adult lung, or bronchial epithelia.
MC3R is of particular interest, because it has
been implicated in regulation of energy balance
and modulating neutrophil accumulation in
lung inflammation, which are both relevant to
CF lung disease (Savastano et al. 2009). Studies
are underway to define the mechanism of lung
disease in CF that reflects the linkage signal at
chr20p13.2.
Meconium Ileus
The high heritability of MI certainly suggested
that genes other than CFTR must be involved,
and the availability of high density markers
throughout the genome provided the opportu-
nity to carry out linkage studies at high resolu-
tion. Using this approach, Blackman and col-
leagues found by genome-wide analyses several
regions of suggestive linkage (logarithm of the
odds of linkage .2.0) for contributing to, or
protecting from development of, meconium il-
eus. These regions were found on chromosomes
4q35.1, 8p23.1, and 11q25 (MI contributing
loci) and chromosomes 20p11.22 and 21q22.3
(protective loci) (Blackman et al. 2006).
The locus on chromosome 8 is a gene-dense
region and was followed up by haplotype anal-
ysis and identified a three polymorphism hap-
lotype that most strongly associated and corre-
sponded to a gene, MSRA, encoding an enzyme,
methionine sulfoxide reductase A, that main-
tains the amino acid methonine in a reduced
state. This candidate was then examined func-
tionally by assessing its effect on obstruction in
a CF mouse model lacking functional MsrA,
and found to dramatically decrease the inci-
dence of obstruction compared to CF mice
with functional MsrA (Henderson et al. 2012).
Another linkage study provided evidence for
MI-influencing loci on chromosome 12p13.3.
Using densely spaced markers in the 12p13.3
region in a cohort of pancreatic insufficient Ca-
nadian CF patients with and without MI, one
gene, ADIPOR2 in MI ( p ¼ 0.002), was impli-
































Figure 3. A locus-zoom plot of association in the GMS and CGS F508del homozygotes at chr11p13 EHF/APIP
region, showing both genotyped and HapMap-imputed SNPs. Colors represent HapMap CEU linkage disequi-
librium r2 with the most significant genotyped SNP (rs12793173; p ¼ 3  1028). The secondary genotyped
peak (rs286873) has low r2 with the primary peak. Addition of the imputed SNPs to genotyped SNPs illustrates
the coverage and LD blocks across the region.
M.R. Knowles and M. Drumm



















distorted from Hardy-Weinberg proportions,
but only in the MI group. The deviation from
expected proportions suggests a causative effect
and the association was replicated in an inde-
pendent sample of CF families. A second locus,
but this one protective, was found on chromo-
some 4q13.3 and one candidate gene in the re-
gion, SLC4A4, a member of the solute transport
family of proteins, showed evidence of associa-
tion ( p ¼ 0.002) (Dorfman et al. 2009).
Association studies can also be used to iden-
tify genes involved in meconium ileus, and a
novel modification of the association approach
has identified several candidate genes. This ap-
proach, termed “informed GWAS” incorporates
functional annotation into the analyses, giving
higher import to those genes with a particular
function attributed to them. Using a model in
which genes influencing epithelial function were
the focus, polymorphisms near SLC6A14 on the
X chromosome and SLC26A9 on chromosome 1
accounted for 5% of variance in MI and these
associations were replicated in an independent
sample of affected individuals (Sun et al. 2012).
Other
Genome-wide association data have not yet been
reported for CFRD or CFLD, although the
Consortium is analyzing data from GWAS1,
and awaiting data from GWAS2.
CONCLUDING REMARKS
The ability to identify genes, or genomic regions,
that influence disease processes hold enormous
promise for better understanding those process-
es and for manipulating them for therapeutic
gain. However, an important caveat of genetic
screens is that they may identify genes involved
in a process, but as such they are only markers;
they do not provide information about the
mechanisms by which the variants exert their
phenotypic effects. Thus, for the results of any
genetic study to have more than prognostic val-
ue, the genes must be followed up by functional
studies to have clinical utility.
The potential for clinical application is not
only great, it is near. There are already approved
drugs that target the protein product encoded
by several of the genes identified (Table 2), in-
cluding antagonists to the endothelin and an-
giotensin receptors, drugs that alter TGF-b1
signaling and small molecule screening pro-
vides the potential to rapidly identify new drugs
that will target these gene products or the path-
ways in which they act.
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